329 related articles for article (PubMed ID: 26597192)
21. Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment.
Mullins C; Beaulac K; Sylvia L
Ann Pharmacother; 2020 Jun; 54(6):526-532. PubMed ID: 31786964
[No Abstract] [Full Text] [Related]
22. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.
Aithal GP
Liver Int; 2015 Jul; 35(7):1801-8. PubMed ID: 25809692
[TBL] [Abstract][Full Text] [Related]
23. Causality assessment for suspected DILI during clinical phases of drug development.
Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
[TBL] [Abstract][Full Text] [Related]
24. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data.
Shin J; Hunt CM; Suzuki A; Papay JI; Beach KJ; Cheetham TC
Pharmacoepidemiol Drug Saf; 2013 Feb; 22(2):190-8. PubMed ID: 23258383
[TBL] [Abstract][Full Text] [Related]
25. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis.
Teschke R; Danan G
Medicines (Basel); 2020 Sep; 7(10):. PubMed ID: 33003400
[No Abstract] [Full Text] [Related]
26. A revised electronic version of RUCAM for the diagnosis of DILI.
Hayashi PH; Lucena MI; Fontana RJ; Bjornsson ES; Aithal GP; Barnhart H; Gonzalez-Jimenez A; Yang Q; Gu J; Andrade RJ; Hoofnagle JH
Hepatology; 2022 Jul; 76(1):18-31. PubMed ID: 35014066
[TBL] [Abstract][Full Text] [Related]
27. Value of liver biopsy in the diagnosis of drug-induced liver injury.
Ahmad J; Barnhart HX; Bonacini M; Ghabril M; Hayashi PH; Odin JA; Rockey DC; Rossi S; Serrano J; Tillmann HL; Kleiner DE;
J Hepatol; 2022 May; 76(5):1070-1078. PubMed ID: 35074471
[TBL] [Abstract][Full Text] [Related]
28. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
[TBL] [Abstract][Full Text] [Related]
29. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
[TBL] [Abstract][Full Text] [Related]
30. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future.
Danan G; Teschke R
Front Pharmacol; 2019; 10():853. PubMed ID: 31417407
[TBL] [Abstract][Full Text] [Related]
31. A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development.
Hermann RP; Rockey DC; Suzuki A; Merz M; Tillmann HL
Aliment Pharmacol Ther; 2022 Apr; 55(8):1028-1037. PubMed ID: 35266155
[TBL] [Abstract][Full Text] [Related]
32. Comparison of laboratory threshold criteria in drug-induced liver injury detection algorithms for use in pharmacovigilance.
Tan EH; Ling ZJ; Ang PS; Sung C; Dan YY; Tai BC
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1480-1488. PubMed ID: 32844466
[TBL] [Abstract][Full Text] [Related]
33. Review article: drug-induced liver injury in clinical practice.
Björnsson E
Aliment Pharmacol Ther; 2010 Jul; 32(1):3-13. PubMed ID: 20374223
[TBL] [Abstract][Full Text] [Related]
34. Case definition and phenotype standardization in drug-induced liver injury.
Aithal GP; Watkins PB; Andrade RJ; Larrey D; Molokhia M; Takikawa H; Hunt CM; Wilke RA; Avigan M; Kaplowitz N; Bjornsson E; Daly AK
Clin Pharmacol Ther; 2011 Jun; 89(6):806-15. PubMed ID: 21544079
[TBL] [Abstract][Full Text] [Related]
35. Idiosyncratic drug hepatotoxicity: a 2008 update.
Andrade RJ; López-Ortega S; López-Vega MC; Robles M; Cueto I; Lucena MI
Expert Rev Clin Pharmacol; 2008 Mar; 1(2):261-76. PubMed ID: 24422651
[TBL] [Abstract][Full Text] [Related]
36. How to Diagnose and Exclude Drug-Induced Liver Injury.
Watkins PB
Dig Dis; 2015; 33(4):472-6. PubMed ID: 26159261
[TBL] [Abstract][Full Text] [Related]
37. Role of liver biopsy in the era of clinical prediction scores for "drug-induced liver injury" (DILI): experience of a tertiary referral hospital.
Costa-Moreira P; Gaspar R; Pereira P; Lopes S; Canão P; Lopes J; Carneiro F; Macedo G
Virchows Arch; 2020 Oct; 477(4):517-525. PubMed ID: 32377873
[TBL] [Abstract][Full Text] [Related]
38. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?
Vuppalanchi R; Liangpunsakul S; Chalasani N
Am J Gastroenterol; 2007 Mar; 102(3):558-62; quiz 693. PubMed ID: 17156142
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced liver injury: a safety review.
García-Cortés M; Ortega-Alonso A; Lucena MI; Andrade RJ;
Expert Opin Drug Saf; 2018 Aug; 17(8):795-804. PubMed ID: 30059261
[TBL] [Abstract][Full Text] [Related]
40. A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury.
Overby CL; Pathak J; Gottesman O; Haerian K; Perotte A; Murphy S; Bruce K; Johnson S; Talwalkar J; Shen Y; Ellis S; Kullo I; Chute C; Friedman C; Bottinger E; Hripcsak G; Weng C
J Am Med Inform Assoc; 2013 Dec; 20(e2):e243-52. PubMed ID: 23837993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
